September 5, 2017 08:44 AM EDTUpdated 09:27 AM
News Briefing

Can­cer vax biotech Amal grabs $10M round; Glob­al Blood Ther­a­peu­tics eyes PRV with new FDA des­ig­na­tion

Shehla Shakoor

Managing Director

⇨ Gene­va-based Amal Ther­a­peu­tics has picked up about $10 mil­lion in Se­ries B mon­ey for its work on pep­tide-based can­cer vac­cines. Boehringer In­gel­heim Ven­ture …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times